14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
XRN vs CHCT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Community Healthcare Trust Incorporated (CHCT) is the stronger overall head-to-head candidate over XRN (XRN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XRN carries a Unified Composite Score of 45.3/100 (HOLD) at $25.79 (N/M Forward P/E, N/A operating margin), whereas CHCT carries 28.1/100 (SELL) at $14.52 (37.3x Forward P/E, 28.1% operating margin).
Composite vs. Pillar Nuance: While XRN currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. CHCT 28.1/100 SELL), CHCT captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (28.1% vs. N/A operating margin) and revenue trajectory (+4.4% vs. N/A YoY).
Technical & Structure Timing Caution: XRN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.5); meanwhile CHCT trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 58.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XRN vs CHCT. Trailing 12-month operating profitability (XRN N/A vs CHCT 28.1%) and valuation multiples (XRN N/M vs CHCT 37.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the REIT - Healthcare Facilities value chain with $422.8M market capitalization and 28.1% operating margin.
OpEx & R&D Reinvestment52.7% of Rev ($66M)
90D Engineering Disclosures0 Published
Investor FAQ XRN vs CHCT Key Questions & Quantitative Answers
As of Nov 17, 2026, Community Healthcare Trust Incorporated (CHCT) is the stronger overall head-to-head candidate over XRN (XRN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XRN carries a Unified Composite Score of 45.3/100 (HOLD) at $25.79 (N/M Forward P/E, N/A operating margin), whereas CHCT carries 28.1/100 (SELL) at $14.52 (37.3x Forward P/E, 28.1% operating margin). Composite vs. Pillar Nuance: While XRN currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. CHCT 28.1/100 SELL), CHCT captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (28.1% vs. N/A operating margin) and revenue trajectory (+4.4% vs. N/A YoY). Technical & Structure Timing Caution: XRN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.5); meanwhile CHCT trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 58.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CHCT leads the Growth & Scale pillar: XRN posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CHCT at +4.4% YoY revenue growth and +179.9% YoY earnings growth on $126M TTM revenue (80.8% gross margin, 28.1% operating margin). On trailing 12-month operating scale, XRN generates N/A in USD-normalized revenue versus $126M for CHCT. In operating R&D and SG&A reinvestment, XRN deploys N/A (0 90-day corporate R&D disclosures) versus 52.7% of Rev ($66M) (0 disclosures) for CHCT.
CHCT screens cheaper on headline valuation multiples. XRN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CHCT trades at 37.3x Forward P/E, 20.1x Trailing P/E, N/M PEG, and 3.4x EV/Revenue (63.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XRN (N/A ROE) versus CHCT (5.3% ROE) capital efficiency.
In options market volatility and institutional positioning, XRN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.50β · 47% Vol realized risk). By comparison, CHCT carries 38.6% implied volatility (35th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 45% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.